Postpartum Preeclampsia Symptoms And Causes

Get health & wellness advice into your inbox

Your privacy is important to us. Any information you provide to us via this website may be placed by us on servers. If you do not agree to these placements, please do not provide the information.

Best Milk Alternative

Overview

Are you a new parent looking for answers regarding symptoms you are facing after birth, for example, high blood pressure? Giving birth takes a heavy toll on the body and may be associated with some illnesses. One is known as postpartum preeclampsia, which will be the focus of our topic today. Preeclampsia is one of the leading causes of maternal death and mortality worldwide. It can involve short or long-term complications.1

So, what is postpartum preeclampsia (PE)? It is a condition that can occur after childbirth. It is characterised by high blood pressure (≥ 140/90), proteinuria (≥300mg in 24-hr urine sample) and damage to organs. The organs most commonly affected are the liver and the kidneys.2 Preeclampsia itself is a pregnancy-related condition. It occurs either immediately (within the first 48 hours) or delayed (48 hours to 6 weeks after delivery).3 If preeclampsia persists or develops after childbirth, it is then referred to as postpartum preeclampsia.

Hypertensive disorders of pregnancy can increase complications during pregnancy by 10-20%.3 Most cases are diagnosed during the antepartum period. However, postpartum PE is recognised as an important factor in maternal morbidity.3 

There are several risk factors for postpartum PE. These risk factors include age, race, obesity and caesarean delivery.3 All of these factors can increase the risk of PE. Most women with a delayed onset of postpartum PE have symptoms within 7-10 days after delivery. These are usually associated with neurological symptoms (for example, headaches).3 Hence, it is important to shed light on this topic and diagnose it ASAP to have the proper care and interventions. This is vital because this condition can progress to severe preeclampsia, eclampsia or HELLP (haemolysis, elevated liver enzymes, and low platelets) syndrome rapidly.2,4

Symptoms of postpartum preeclampsia

There are multiple signs and symptoms of postpartum PE, including:2,4,5,6

  • Hypertension (persistent high blood pressure (≥ 140/90)
  • Proteinuria (the presence of different and persistent amounts of protein in the urine). This can be a sign of kidney damage. It can also lead to increased risk of cardiovascular disease. Hence, it is important to test for the presence of these proteins. This is usually done through urine dipstick, blood pressure, albumin/creatinine ratio and serum creatinine tests
  • Severe headaches that do not go away
  • Visual changes and disturbances
  • Swelling (oedema) in the face and hands
  • Nausea and vomiting
  • Stomach pain
  • Shortness of breath
  • Seizures
  • Strokes
  • Organ damage
  • Death

Causes and origin of postpartum preeclampsia

There is no single definitive cause for postpartum PE. However, contributing factors were suggested to include placental dysfunction and an altered immune system. This results in poor uteroplacental perfusion, leading to placental hypoxia (low oxygen). This is seen as stage 1.2 

The consequence of stage 1 is the release of soluble factors into the mother's circulation. These soluble factors bring about stage 2. Stage 2 consists of systemic endothelial dysfunction and hypertension.2 Aside from the cause, certain risk factors can contribute to the development of postpartum PE (Table 1).

Table 1. Clinical risk factors of PE2

Moderate risk factors
Obesity
Family history of PE
Black race
Lower-income
>35 years of age
Previous pregnancy complications
>10 years between pregnancies
In vitro fertilisation
Major risk factors
History of PE
Multifetal pregnancies (twins, triplets, etc)
Chronic hypertension
Pregestational diabetes
Kidney disease
Autoimmune disease

Diagnosis and detection of preeclampsia

Diagnosis of PE is well established. It is usually done by monitoring blood pressure, urine analysis (urinalysis), and physical examination.2 The diagnostic criteria for preeclampsia are listed below.

  • Blood pressure:
    • Before pregnancy: blood pressure elevations (≥ 140/90) diagnosed before 20 weeks on 2 occasions at least 4 hours apart
    • During pregnancy: 2 elevated blood pressure readings (≥140/90) after 20 weeks on 2 occasions at least 4 hours apart
  • Urinalysis: 300 mg protein or more in a 24-hour urine sample; a protein/creatinine ratio of 0.3 or higher on urine dipstick; 2+ protein on urine dipstick

Management and treatment options of postpartum PE

There are multiple treatment options. Delivery, in most cases, is the acute treatment. However, it is not a cure. According to James N. Martin (MD, past president of the American College of Obstetricians and Gynaecologists and member of the Preeclampsia Foundation Medical Advisory Board): “It takes time for the uterus to shed its lining after birth, so this process may be behind the delay that's sometimes seen in [postpartum preeclampsia] after delivery”.4 Other forms of treatment are listed in Table 2.

Table 2. Approach to managing postpartum PE3

Management approaches
Short-acting anti-hypertensive medications-Administered within 30–60 minutes
-Threshold for treatment: BP (blood pressure) ≥160/110 mmHg
-Goal BP: <150/100 mmHg
-Examples: intravenous (IV) labetalol or hydralazine, oral nifedipine
Long-acting anti-hypertensive medications-Administered to maintain BPs <140s-150s/90s-100s
-Examples: oral labetalol, oral extended-release nifedipine 
Magnesium for seizure prophylaxis-Recommended for women with neurologic symptoms
-Evaluation of possible risks and benefits for women with other severe features, particularly after 1 week postpartum
Diuretics-Guided by clinical assessment of volume status
-Should be administered routinely in women with pulmonary oedema or significant fluid overload
-Examples: most commonly, IV or oral furosemide
Follow-up-Home BP monitoring and management where possible; if not possible, a short-interval in-office
-BP check (within 5–7 days) is recommendedBP assessment at a comprehensive postpartum visit
-Education on the long-term consequences associated with hypertensive disorders of pregnancy
-Education on risk factor identification and management 
-Assessment of BP at least once a year

Note: BP = blood pressure, IV: intravenous

Prevention and risk reduction

Prevention and risk reduction in PE can be handled through regular prenatal check-ups. These can consist of regular blood pressure monitoring as well as urinalysis for early detection of proteinuria. Furthermore, lifestyle modifications and adjustments are just as important.

A healthy diet, exercise, and weight management can improve blood pressure and make the appearance of PE less likely. Additionally, it is important for healthcare clinicians to stay updated with new advancements in science (including PE) and relay this information to their patients.

This can help detect early signs of the illness and provide a personalised plan for illness management/prevention. It is also important to continue with a postpartum follow-up session to detect any changes in blood pressure. This is important since PE can manifest 6 weeks after delivery, as mentioned before.

Research recommendations

There are still many unanswered questions when it comes to the aetiology, diagnosis, and management of postpartum preeclampsia. These gaps in knowledge are addressed in Table 3.

Table 3. Future research gaps and priorities in postpartum PE3

Gaps in knowledgeProposed methods and specific questions
Determination of the disease incidence and risk factors-Measurement of postpartum blood pressure (BP) following uncomplicated deliveries
-Telehealth and remote monitoring may be useful to address this gap
In-depth understanding of the aetiology and pathophysiology-Identification of prospective biomarkers both before the onset of the disease and at the time of diagnosis
-Placenta pathology to evaluate features of poor vascular perfusion, if available
-Biorepositories may assist in answering these questions
Development of evidence-based management algorithms-Studies examining outcomes of different treatments
-Priority should be given to the need for magnesium postpartum and the role of specific antihypertensive agents and routine use of diuretics. Determining the optimal threshold for acute treatment and targets is also important. Priority should also be given to the development of the most effective strategies for patient and clinician education regarding postpartum preeclampsia recognition and diagnosis
Understanding the risk of recurrence and future pregnancy risk, as well as optimal management-Large-scale multi-centre studies will likely be needed to address these questions
-Example 1: Evaluating the use of low-dose aspirin in future pregnancies and postpartum prophylaxis with home BP monitoring 
-Example 2: Evaluating the use of diuretics in future pregnancies
Assessing the future risk to maternal health-Clear definitions and classification will aid in the determination of future cardiovascular risk
-Of particular interest is the risk of heart failure among women with postpartum PE. This risk is known to be increased among pregnant women with preeclampsia 

Summary

Postpartum preeclampsia is an illness that contributes massively to maternal and foetal morbidity and mortality. Understanding how to prevent and treat this disorder is crucial to improving maternal and foetal health.

An accurate understanding of preeclampsia and disease progression development is important in improving patient care. It would also allow the prevention of unfortunate outcomes. PE significantly impacts overall heart health and the development of future cardiovascular disease.

PE also affects the development of chronic hypertension and liver, kidney and neurologic consequences. This disease has important immediate and long-term effects on the newborn child. This further illustrates the importance of accurate treatment and prevention of PE.

Given the enormity of this impact on short-term and long-term health, more research looking into ways to prevent this disease is needed. Additionally, particular emphasis should be placed on long-term follow-up after a pregnancy complicated by PE.

References

  1. Srajer A, Johnson JA, Yusuf K. Preeclampsia and postpartum mental health: mechanisms and clinical implications. The Journal of Maternal-Fetal & Neonatal Medicine [Internet]. 2024 Mar 6 [cited 2024 Mar 15];35(25):8443–9. Available from: https://www.tandfonline.com/doi/full/10.1080/14767058.2021.1978067
  2. Bisson C, Dautel S, Patel E, Suresh S, Dauer P, Rana S. Preeclampsia pathophysiology and adverse outcomes during pregnancy and postpartum. Front Med [Internet]. 2023 Mar 16 [cited 2024 Mar 15];10. Available from: https://www.frontiersin.org/articles/10.3389/fmed.2023.1144170
  3. Hauspurg A, Jeyabalan A. Postpartum preeclampsia/eclampsia: Defining its place and management among the hypertensive disorders of pregnancy. American Journal of Obstetrics & Gynecology [Internet]. 2021 Jul 6 [cited 2024 Mar 15];226(2):S1211-S1221. Available from: https://www.ajog.org/article/S0002-9378(20)31201-1/fulltext
  4. Website. Preeclampsia Foundation - Saving mothers and babies from preeclampsia. [cited 2024 Mar 15]. Preeclampsia - postpartum preeclampsia. Available from: https://www.preeclampsia.org/postpartum-preeclampsia
  5. Gorriz JL, Martinez-Castelao A. Proteinuria: detection and role in native renal disease progression. Transplantation Reviews [Internet]. 2012 Jan 1 [cited 2024 Mar 15];26(1):3–13. Available from: https://www.sciencedirect.com/science/article/pii/S0955470X11000875
  6. Proteinuria | the UK kidney association [Internet]. [cited 2024 Mar 15]. Available from: https://ukkidney.org/health-professionals/information-resources/uk-eckd-guide/proteinuria

Get health & wellness advice into your inbox

Your privacy is important to us. Any information you provide to us via this website may be placed by us on servers. If you do not agree to these placements, please do not provide the information.

Best Milk Alternative
[optin-monster-inline slug="yw0fgpzdy6fjeb0bbekx"]
This content is purely informational and isn’t medical guidance. It shouldn’t replace professional medical counsel. Always consult your physician regarding treatment risks and benefits. See our editorial standards for more details.

Get our health newsletter

Get daily health and wellness advice from our medical team.
Your privacy is important to us. Any information you provide to this website may be placed by us on our servers. If you do not agree do not provide the information.

Tatiana Abdul Khalek

PhD, Anglia Ruskin University, UK

I am a PhD student in Biomedical Science at Anglia Ruskin university and work as a quality control (QC) analyst (microbiology/chemistry) at EuroAPI. I have a MSc in Forensic Science from Anglia Ruskin (Cambridge) and I had experience in different roles such as quality lab technician at Fluidic Analytics, Research Assistant/Lab Manager at Cambridge University and Forensic Analyst at the The Research Centre in Topical Drug Delivery and Toxicology, University of Hertfordshire.

My PhD revolves around the use of nanoparticles and their role in cartilage degradation, as well as their potential as drug delivery vehicles for the treatment of diseases such as leukaemia.

Leave a Reply

Your email address will not be published. Required fields are marked *

my.klarity.health presents all health information in line with our terms and conditions. It is essential to understand that the medical information available on our platform is not intended to substitute the relationship between a patient and their physician or doctor, as well as any medical guidance they offer. Always consult with a healthcare professional before making any decisions based on the information found on our website.
Klarity is a citizen-centric health data management platform that enables citizens to securely access, control and share their own health data. Klarity Health Library aims to provide clear and evidence-based health and wellness related informative articles. 
Email:
Klarity / Managed Self Ltd
Alum House
5 Alum Chine Road
Westbourne Bournemouth BH4 8DT
VAT Number: 362 5758 74
Company Number: 10696687

Phone Number:

 +44 20 3239 9818
arrow-right